NO20060506L - Indol-7-yl sulfonamid derivater, deres fremstilling og deres anvendelse i medikamenter - Google Patents

Indol-7-yl sulfonamid derivater, deres fremstilling og deres anvendelse i medikamenter

Info

Publication number
NO20060506L
NO20060506L NO20060506A NO20060506A NO20060506L NO 20060506 L NO20060506 L NO 20060506L NO 20060506 A NO20060506 A NO 20060506A NO 20060506 A NO20060506 A NO 20060506A NO 20060506 L NO20060506 L NO 20060506L
Authority
NO
Norway
Prior art keywords
drugs
preparation
sulfonamide derivatives
indol
diastereomers
Prior art date
Application number
NO20060506A
Other languages
English (en)
Inventor
Alberto Dordal Zueras
Xavier Codony Soler
Vidal Ramon Merce
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of NO20060506L publication Critical patent/NO20060506L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)

Abstract

Foreliggende oppfinnelse refererer til nye sulfonamid derivater, med generell formel (la, lb, Ic), eventuelt i form av en av deres stereoisomerer, fortrinnsvis enantiomerer eller diastereomerer, deres racemater, eller i form av en blanding av minst to av deres stereoisomerer, fortrinnsvis enantiomerer eller diastereomerer, i et hvilket som helst blandingsforhold, eller deres salter, fortrinnsvis de tilsvarende, fysiologisk akseptable saltene, eUer tilsvarende solvater; fremgangsmåter for deres fremstilling, deres anvendelse som medikamenter i human og/eller veterinære terapier, og farmasøytiske sammensetningene som inneholder dem.
NO20060506A 2003-07-30 2006-01-31 Indol-7-yl sulfonamid derivater, deres fremstilling og deres anvendelse i medikamenter NO20060506L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200301808A ES2222830B1 (es) 2003-07-30 2003-07-30 Derivados de 7-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
PCT/EP2004/008513 WO2005013979A1 (en) 2003-07-30 2004-07-29 Indol-7 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators

Publications (1)

Publication Number Publication Date
NO20060506L true NO20060506L (no) 2006-01-31

Family

ID=34130542

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060506A NO20060506L (no) 2003-07-30 2006-01-31 Indol-7-yl sulfonamid derivater, deres fremstilling og deres anvendelse i medikamenter

Country Status (23)

Country Link
US (1) US7414070B2 (no)
EP (1) EP1648444B1 (no)
JP (1) JP2007500167A (no)
KR (1) KR20060036457A (no)
CN (1) CN1832739A (no)
AR (1) AR045158A1 (no)
AT (1) ATE432698T1 (no)
AU (1) AU2004262487A1 (no)
BR (1) BRPI0413001A (no)
CA (1) CA2534136A1 (no)
DE (1) DE602004021383D1 (no)
EC (1) ECSP066323A (no)
ES (2) ES2222830B1 (no)
IL (1) IL172750A0 (no)
MX (1) MXPA06001130A (no)
NO (1) NO20060506L (no)
NZ (1) NZ545298A (no)
PE (1) PE20050352A1 (no)
PT (1) PT1648444E (no)
RU (1) RU2006105791A (no)
TW (1) TW200510433A (no)
WO (1) WO2005013979A1 (no)
ZA (1) ZA200600418B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2018861A1 (en) * 2007-07-26 2009-01-28 Laboratorios del Dr. Esteve S.A. 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain
ES2358288T3 (es) 2007-08-01 2011-05-09 Laboratorios Del Dr. Esteve S.A. Combinación de al menos dos ligandos de 5ht6.
EP2053052A1 (en) 2007-10-23 2009-04-29 Laboratorios del Dr. Esteve S.A. Process for the preparation of 6-substituted imidazo[2,1-b]thiazole-5-sulfonyl halide
US20190336585A1 (en) * 2018-05-03 2019-11-07 John Lawrence Mee Method for sustainable human cognitive enhancement
US20190390193A1 (en) * 2018-06-23 2019-12-26 John Lawrence Mee Reversible method for sustainable human cognitive enhancement

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472870A (en) * 1966-08-29 1969-10-14 Mead Johnson & Co Sulfonamidotryptamines
US5939451A (en) 1996-06-28 1999-08-17 Hoffmann-La Roche Inc. Use of sulfonamides
TWI242011B (en) * 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
DE19753522A1 (de) * 1997-12-03 1999-06-10 Boehringer Ingelheim Pharma Substituierte Indole, ihre Herstellung und ihre Verwendung als Arzneimittel
JP2002167376A (ja) * 2000-11-30 2002-06-11 Mercian Corp 血管内皮細胞増殖因子発現抑制作用を有するインドール誘導体及びその用途
EP1377580B1 (en) * 2001-01-30 2006-09-27 Eli Lilly And Company Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor
US6488243B2 (en) * 2001-04-06 2002-12-03 Seong Tae Kim Bag holder for hanging on rims of miscellaneous items
ES2187300B1 (es) * 2001-11-14 2004-06-16 Laboratorios Del Dr. Esteve, S.A. Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
DE602004016491D1 (de) 2003-05-09 2008-10-23 Esteve Labor Dr Verwendung von sulfonamid-derivate zur herstellung eines medikaments für die vorbeugung oder behandlung von essstörungen

Also Published As

Publication number Publication date
TW200510433A (en) 2005-03-16
ES2222830A1 (es) 2005-02-01
JP2007500167A (ja) 2007-01-11
BRPI0413001A (pt) 2006-09-26
DE602004021383D1 (de) 2009-07-16
ECSP066323A (es) 2006-08-30
IL172750A0 (en) 2006-04-10
AU2004262487A1 (en) 2005-02-17
MXPA06001130A (es) 2006-04-24
ZA200600418B (en) 2007-03-28
KR20060036457A (ko) 2006-04-28
RU2006105791A (ru) 2007-09-20
ES2222830B1 (es) 2006-02-16
CA2534136A1 (en) 2005-02-17
PE20050352A1 (es) 2005-06-12
EP1648444B1 (en) 2009-06-03
ATE432698T1 (de) 2009-06-15
US7414070B2 (en) 2008-08-19
EP1648444A1 (en) 2006-04-26
CN1832739A (zh) 2006-09-13
AR045158A1 (es) 2005-10-19
PT1648444E (pt) 2009-09-03
ES2327846T3 (es) 2009-11-04
WO2005013979A1 (en) 2005-02-17
NZ545298A (en) 2008-06-30
US20070185207A1 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
NO20060682L (no) Indol-6 sulfonamid derivater, deres fremstilling og deres anvendelse 5-HT-6 som modulatorer
NO20060865L (no) Indol-5-YL sulfonamid derivater, deres fremstilling og deres anvedelse 5-HT-6 som modulatorer
NO20060155L (no) Indol-4-sulfonamid derivater, deres fremstilling og deres anvendelse 5-HT-6 som modulatorer
NO20060342L (no) 1-sulfonylindol derivater, deres fremstilling og deres andvendelse som 5-HT6 ligander
NO20044826L (no) Pyrrolidinderivater
NO20060908L (no) Substituerte tazol-benzoisotiazoldioksidderivater, deres fremstilling og anvendelse
NO20081844L (no) Terapeutiske forbindelser
TW200613243A (en) Novel compounds
HK1120725A1 (en) Tetrahydro-beta-carbolin-sulfonamide derivatives as 5-ht6ligands
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20055492L (no) Anvendelse av sulfonamidderivater for fremstilling av et medikament for profylakse og/eller behandling av lidelser ved matinntak
MY139303A (en) Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
UY27350A1 (es) Azaindoles
TW200626553A (en) Novel compounds
ES2340502T3 (es) Compuestos de 1,4,8-triazaespiro(4,5)decan-2-ona sustituidos para el tratamiento de la obesidad.
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
ES2328496T3 (es) Compuestos de 1,4,8-triaza-espiro(4,5)decan-2-ona sustituidos.
NO20091766L (no) Spiro-piperidinderivater
NO20060506L (no) Indol-7-yl sulfonamid derivater, deres fremstilling og deres anvendelse i medikamenter
NO20050903L (no) Nye piperazinyl-pyrazinonderivater for behandling av 5HT-2A reseptorrelaterte forstyrrelser
NO20080669L (no) Acetylenpiperaziner som metabotrofiske glutamatreseptorantagonister
DK1124841T3 (da) Substituerede phenylalkenoylguanidiner, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler eller diagnosemidler og lægemidler, som indeholder dem
NO20080671L (no) Bisykliske piperaziner som metabotrofiske glutamatreseptorantagonister
NO20091830L (no) Spiro-piperidinderivater som VIa reseptorantagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application